Company Information

Company Profile

Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.

LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.

Latest Presentations


Cerecor | AEVI Merger Details

Please see the attached to documents for detailed information regarding the Aevi acquisition / merger and or a simple question and answer document

Name View Document
CERECOR SEC S4 Aevi Acquisition Download
CERECOR Q&A Document Download

Contact Information

Investor Relations
Avalo Therapeutics

ICR Westwicke
Chris Brinzey
Managing Director
T: 339-970-2843

Company Contact
Avalo Therapeutics, Inc.
1500 Liberty Ridge Drive
Wayne, PA 19087